Co-blockade reduced primary tumour mass (ST2–/– + antiPD1 vs. WT= 1,9 vs. 2,8 g) and volume (ST2–/– + antiPD1 vs. WT= 450 vs. 900 mm3) by ∼50%, and prolonged survival of treated animals [108]. The gene discussed is IL1RL1; the disease is neoplasm.